Octaaminoacridine

Summary

Octaaminoacridine (CHEMBL263198) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 202.3 Da · C13H18N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL263198
Name	Octaaminoacridine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	115097
Molecular formula	C13H18N2
Molecular weight	202.3
InChIKey	BMRFESVZYWRROS-UHFFFAOYSA-N

SMILES: C1CCC2=C(C1)C(=C3CCCCC3=N2)N

IUPAC name: 1,2,3,4,5,6,7,8-octahydroacridin-9-amine

Also known as: MMV1647374

Parent form; salt/anhydrous children: CHEMBL4297411

Patent coverage: 4 distinct patent families (8 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Acetylcholinesterase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ACHE	6.44	IC50	360	nM	CHEMBL_ACT_281346

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).